PIRS · Pieris Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | $0 | $0 | $53.0K | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $9.33M | - | $3.18M | $5.12M | $4.07M | - | - | $751.0K | $1.22M | - |
| SG&A | $5.52M | - | $3.65M | $4.13M | $3.80M | - | $3.58M | $3.43M | $4.14M | - |
| Total Operating Expenses | $14.86M | - | $10.18M | $9.25M | $7.87M | - | $3.13M | $4.18M | $5.36M | - |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | ($14.86M) | - | ($10.18M) | ($9.25M) | ($7.87M) | - | ($3.13M) | ($4.18M) | ($5.30M) | - |
| Interest Expense | - | - | $220.0K | $29.0K | - | - | - | - | - | - |
| Income Tax | $0 | - | $0 | $0 | $0 | - | - | - | - | - |
| Net Income | ($15.77M) | - | ($11.35M) | ($9.47M) | ($8.19M) | - | ($2.89M) | ($3.59M) | ($4.89M) | - |
| EPS - Basic | ($1.20) | - | ($1.03) | ($0.86) | ($0.74) | - | ($2.19) | ($2.76) | ($3.95) | - |
| EPS - Diluted | ($1.20) | - | ($1.03) | ($0.86) | ($1.54) | - | ($2.19) | ($2.76) | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $206.39M | $57.98M | $63.57M | $70.43M | $75.63M | $83.60M | $19.36M | $19.73M | $19.08M | $17.40M |
| Accounts Receivable | - | $0 | $0 | $0 | $0 | $358.0K | $373.0K | $1.49M | $1.84M | $572.0K |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $5.44M | $4.59M | $3.48M | $4.56M | $4.44M | $4.59M | $801.0K | $969.0K | $1.52M | $3.37M |
| Current Assets | $263.23M | $58.99M | $66.94M | $73.75M | $79.44M | $88.23M | - | - | - | $38.68M |
| Total Assets | $263.76M | $59.56M | $66.94M | $73.75M | $79.44M | $88.23M | $20.52M | $25.05M | $29.50M | $38.68M |
| Current Liabilities | $9.12M | $11.34M | $10.31M | $9.62M | $8.98M | $12.04M | $4.25M | $6.35M | $7.53M | $11.92M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $31.45M | $31.58M | $28.25M | $25.97M | $23.86M | $25.63M | - | - | - | $11.92M |
| Stockholders' Equity | $232.31M | $27.98M | $38.68M | $47.78M | $55.58M | $62.61M | $16.27M | $18.70M | $21.96M | $26.76M |
| Retained Earnings | ($151.22M) | ($135.45M) | ($122.74M) | ($111.39M) | ($101.92M) | ($93.73M) | ($326.33M) | ($323.45M) | ($319.86M) | ($314.96M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($10.86M) | - | - | - | ($6.77M) | - | - | - | ($7.00M) | - |
| Investing Cash Flow | $0 | - | - | - | - | - | - | - | $9.00M | - |
| Financing Cash Flow | $214.73M | - | - | - | $0 | - | - | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | $0 | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | ($7.00M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | -10005.7% | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | -9230.2% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | -13200.0% | - |
| FCF / Net income | - | - | - | - | - | - | - | - | 1.43 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | 2298.1% | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | 7807.5% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -6.0% | - | -16.9% | -12.8% | -10.3% | - | -14.1% | -14.3% | -16.6% | - |
| Return on equity | -6.8% | - | -29.3% | -19.8% | -14.7% | - | -17.7% | -19.2% | -22.3% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 28.88 | 5.20 | 6.49 | 7.67 | 8.84 | 7.33 | - | - | - | 3.24 |
| Quick ratio | 28.88 | 5.20 | 6.49 | 7.67 | 8.84 | 7.33 | - | - | - | 3.24 |
| Cash ratio | 22.64 | 5.11 | 6.16 | 7.32 | 8.42 | 6.94 | 4.55 | 3.11 | 2.53 | 1.46 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | -46.3x | -319.0x | - | - | - | - | - | - |
| Equity multiplier | 1.14 | 2.13 | 1.73 | 1.54 | 1.43 | 1.41 | 1.26 | 1.34 | 1.34 | 1.45 |
| Liabilities / Assets | 0.12 | 0.53 | 0.42 | 0.35 | 0.30 | 0.29 | - | - | - | 0.31 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | 12685d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | -100.0% | -100.0% | -97.3% | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | -85.0% | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | -63.8% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -88.7% | - | -224.6% | -121.5% | -48.4% | - | 73.4% | - | 65.8% | - |
| Net income growth (YoY) | -92.6% | - | -293.0% | -163.8% | -67.3% | - | 73.1% | - | 62.9% | - |
| EPS growth (YoY) | 22.1% | - | 53.0% | 68.8% | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | 36.7% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 318.0% | -55.3% | 137.8% | 155.4% | 153.0% | 134.0% | -46.7% | -53.8% | 42.1% | -4.2% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2019-12-31.
Product / service
$46.28M totalCustomer Revenue$43.65M · 94.3%
Collaboration Revenue$2.63M · 5.7%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing PIERIS PHARMACEUTICALS against the 5 most active filers in the same SIC group.